f

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore. Excepteur sint lorem cupidatat.

You may like:

The Space Between: Connecting the Science of Targeted PsA Therapies to Patient Care

The Space Between: Connecting the Science of Targeted PsA Therapies to Patient Care

The Space Between: Connecting the Science of Targeted PsA Therapies to Patient Care

This virtual activity was held in conjunction with Congress of Clinical Rheumatology (CCR) East. Improving care for patients with psoriatic arthritis (PsA) is profoundly boosted by facilitating better patient-provider communication and implementing targeted treatment strategies. This CME activity took participants on a journey to look into the space between science and practice to enhance participants’ adeptness through innovative experiential learning and presentations. The expert presenters demonstrated mechanisms of action (MOAs) of therapies using an interactive animation. They also discussed effectiveness and safety of existing and emerging targeted treatments for PsA and presented on a patient-provider shared decision making. Learners gained expertise in the main pathways of immune activation and built inspiration to translate recent scientific advances into patient-centered care.
 

  • Dr. Desai, Chief of Rheumatology, University of California, Irvine

    Sheetal Desai, MD, MSEd
    Chief of Rheumatology,
    Rheumatology Fellowship Program Director,
    Director, Lupus Clinic
    Associate Clinical Professor of Medicine,
    Division of Rheumatology
    University of California, Irvine
    Irvine, California

  • Dr. Mease, Director, Rheumatology Research, University of Washington School of Medicine

    Philip J. Mease, MD, MACR
    Director,
    Rheumatology Research
    Swedish Medical Center/Providence St. Joseph Health
    Clinical Professor,
    University of Washington School of Medicine
    Seattle, Washington

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative):
    • Marianna Shershneva, MD, PhD; Megan Ragan; and Christine Tebben

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Sheetal Desai, MD, MSEd
    • Consultant: GlaxoSmithKline, Janssen
    • Speaker Bureau: GlaxoSmithKline, Janssen
  • Presenter: Philip J. Mease, MD, MACR
    • Consultant: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun Pharmaceuticals, UCB
    • Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
    • Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun Pharmaceuticals, UCB
  • Planner Faculty: Daniel E. Furst, MD
    • Advisor: Actelion, Amgen, BMS, Boehringer Ingelheim, Corbus, CSL Behring, Galapagos Novartis, Pfizer, Roche/Genentech, Talaris
    • Research: BMS, Corbus, CSL Behring, Galapagos GSK, NIH, Pfizer, Sanofi, Talaris
  • Planner Faculty: Joseph Merola, MD, MMSc
    • Consultant: Merck Research Laboratories, AbbVie, Dermavant, Lilly, Novartis, Janssen, UCB, Celgene, Sanofi Regeneron, Almirall, Sun Pharmaceuticals, Biogen, Pfizer, Incyte, Aclaris, EMD Serono
    • Investigator: Leo Pharma, Kyowa Kirin

As a result of participation in this educational activity, participants should increase their ability to:

  • Describe

    Describe a current model explaining PsA pathophysiology and mechanisms of action of
    targeted therapies for PsA

  • Apply evolving treatment strategies and evidence of effectiveness and safety of targeted therapies for management of patients with PsA

  • Discuss

    Discuss the impact of different PsA disease domains on the patient’s quality of life and patient-reported outcomes measures

  • Engage

    Engage patients with PsA in shared decision making regarding treatment goals, treatment plan, and treatment modification

  • identify

    Identify solutions to COVID-19-related challenges in treatment of PsA

Resources

Unless otherwise specifically prohibited, you may temporarily download one copy of the materials for personal, noncommercial use only. You may not modify or copy the materials, use them for any commercial purpose or public display (commercial or noncommercial), remove any copyright or other proprietary notations, or transfer the materials to another person or online site.

Activity Information

Target Audience
The target audience for this activity was rheumatologists and nurse practitioner/physician assistant rheumatology providers. Other healthcare professionals who treat patients with PsA could benefit from participation.

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designated this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Successful completion of this CME activity, which included participation in the evaluation component, enabled the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants could earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME Content Review
The views and opinions expressed in this activity were those of the faculty and did not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers and two patients with psoriasis and psoriatic arthritis. The reviewers of this activity had no relevant financial relationships to disclose. 

This continuing medical education activity included reference(s) to unlabeled or unapproved uses of drugs. 

Provider
This activity was provided by Forefront Collaborative.

Commercial Support
This activity was supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.